Vulvar And Vaginal Atrophy (Vva) Therapy Market 2023-2035


Posted April 24, 2024 by Prashanth9573

Vulvar And Vaginal Atrophy (Vva) Therapy Market size is expected to reach USD 5 Billion by the end of 2035, growing at a CAGR of 11% during the forecast period, i.e., 2023-2035.

 
Research Nester published a report titled Vulvar and Vaginal Atrophy Therapy Market: Global Demand Analysis & Opportunity Outlook 2035” which delivers detailed overview of the global vulvar and vaginal atrophy (VVA) therapy market in terms of market segmentation by symptoms, diagnosis, treatment, end-user, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global Vulvar And Vaginal Atrophy (Vva) Therapy Market is anticipated to grow with a CAGR of 11% during the forecast period, i.e., 2023-2035. The market is segmented by treatment into non hormonal therapy, hormonal therapy, selective estrogen receptor modulators (SERM), and laser therapy. Out of these, the hormonal therapy segment is anticipated to garner the largest revenue by the end of 2035, owing to the increasing number of cancer cases as the therapy lessens the chances of cancer recurrence. According to the Centers for Disease Control and Prevention, in 2019, about 1,368 women were diagnosed with vaginal cancer in the United States. On the other hand, most women are treated with menopausal hormone therapy (MHT), also known as hormone replacement therapy (HRT), if they have symptoms related to menopause.


An increasing female geriatric population, as well as rising lifestyle-related disorders such as hormonal imbalances, stress, and depression, are expected to drive the growth of the global vulvar and vaginal atrophy therapy market during the forecast period.

Request Report Sample @ https://www.researchnester.com/sample-request-4178

Geographically, the global vulvar and vaginal atrophy therapy market is segmented into five regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Out of these, the market in North America is projected to garner the largest share by the end of 2031. The upsurge in the number of women suffering from pre and postmenopausal hormonal imbalances, as well as the growing number of cancer cases in the region, are some of the major factors anticipated to drive the growth of the market in North America.


Genitourinary Syndrome of Menopause (GSM) to Drive the Market Growth

Menopausal genitourinary syndrome affects approximately 30% to 75% of postmenopausal women and can significantly impair health, sexual function, and quality of life.

The surge in the number of premenopausal, early menopausal and postmenopausal cases as well as increasing genitourinary syndrome of menopause (also known as vulvovaginal atrophy or urogenital trophy) among women globally is driving the vulvar and vaginal atrophy market.


However, unreported cases of genitourinary syndrome of menopause owing to lack of awareness, concerns about vulvar and vaginal atrophy from cancer combination treatments are expected to operate as key restraints to the growth of the global vulvar and vaginal atrophy therapy market over the forecast period.


This report also provides the existing competitive scenario of some of the key players of the global vulvar and vaginal atrophy therapy market which includes company profiling of Dare Bioscience, Inc., Almirall, S.A, Viveve, Inc., Lutronic, Venus Concept, ThermiGen LLC, Alma Lasers, BTL, Fotona, TherapeuticsMD, Inc., and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global vulvar and vaginal atrophy therapy market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Request for customization @ https://www.researchnester.com/customized-reports-4178



Contact for more Info:

AJ Daniel

Email: [email protected]

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By researchnester
Phone +1 646 586 9123
Business Address Noida
Noida
Country India
Categories Business , Marketing
Tags vulvar and vaginal atrophy vva therapy market , vulvar and vaginal atrophy vva therapy market growth , vulvar and vaginal atrophy vva therapy market forecast
Last Updated April 24, 2024